Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL.

Authors
Publication date
3 June 2023
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Ezid

    redirect
    oaiark:/13030/qt5zk1h2jd
    Last time updated on 20/08/2023